Physiologically Speaking

NOVEMBER 24, 2023

Greetings! Welcome to the Physiology Friday newsletter. This week, I’m reposting a post that initially appeared as a paid post in April. I know you’ll enjoy it (or potentially re-enjoy it if you read it already). This newsletter is brought to you by my ebook “VO2 Max Essentials” (on sale for $5 for Black Friday!) and Examine.com.

Physiology 52

Physiology Diet 52

International Journal of Cardiovascular Sciences

NOVEMBER 24, 2023

The Abstract Submission System for the 1st Cardiology Departments Meeting (São Paulo, April 12-14, 2024) is now open! Check the regulations and submit your abstract by January 15th by visiting: [link]. IMPORTANT: Submission is free, but presenters of approved abstracts must be registered. Don’t miss the opportunity to discuss your research with leading experts in the field!

Research 52

Research 52

CardiacWire

NOVEMBER 24, 2023

The Factor XI inhibitor movement hit a setback last week, after Bayer announced that it halted its OCEANIC-AF trial due to asundexian’s lack of efficacy. Investigative Factor XI inhibitors have sparked optimism among cardiologists for their potential to become safer antithrombotics, avoiding anticoagulants’ typical bleeding risks Asundexian is Bayer’s most advanced Factor XIa inhibitor, and already gained two FDA Fast Track Designations (stroke & systemic embolism prevention in Afib patients

AFIB 52

AFIB Embolism Stroke Strokes 52

Physiologically Speaking

NOVEMBER 24, 2023

Greetings! Welcome to the Physiology Friday newsletter. This week, I’m reposting a post that initially appeared as a paid post in April. I know you’ll enjoy it (or potentially re-enjoy it if you read it already). This newsletter is brought to you by my ebook “VO2 Max Essentials” (on sale for $5 for Black Friday!) and Examine.com.

Physiology 52

Physiology Diet 52

European Journal of Heart Failure

NOVEMBER 24, 2023

The different risk of new-onset, chronic, worsening, and advanced heart failure. CI, confidence interval; HF, heart failure; OR, odds ratio. Abstract Aims Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking.

Heart Failure 40

Heart Failure Hospital Outcomes Research 40